KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Globus Medical (GMED) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Globus Medical (GMED) over the last 15 years, with Q3 2025 value amounting to $371.8 million.

  • Globus Medical's Cash & Equivalents fell 4030.36% to $371.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $371.8 million, marking a year-over-year decrease of 4030.36%. This contributed to the annual value of $784.4 million for FY2024, which is 6786.89% up from last year.
  • Globus Medical's Cash & Equivalents amounted to $371.8 million in Q3 2025, which was down 4030.36% from $229.4 million recorded in Q2 2025.
  • In the past 5 years, Globus Medical's Cash & Equivalents ranged from a high of $784.4 million in Q4 2024 and a low of $134.2 million during Q3 2022
  • Over the past 5 years, Globus Medical's median Cash & Equivalents value was $279.6 million (recorded in 2023), while the average stood at $325.2 million.
  • Per our database at Business Quant, Globus Medical's Cash & Equivalents crashed by 6290.91% in 2022 and then skyrocketed by 21056.32% in 2023.
  • Over the past 5 years, Globus Medical's Cash & Equivalents (Quarter) stood at $193.1 million in 2021, then fell by 22.07% to $150.5 million in 2022, then soared by 210.56% to $467.3 million in 2023, then surged by 67.87% to $784.4 million in 2024, then plummeted by 52.61% to $371.8 million in 2025.
  • Its Cash & Equivalents stands at $371.8 million for Q3 2025, versus $229.4 million for Q2 2025 and $461.3 million for Q1 2025.